Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases

Bone Marrow Transplant. 2022 Apr;57(4):681-684. doi: 10.1038/s41409-021-01556-8. Epub 2022 Feb 7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Busulfan / analogs & derivatives
  • Busulfan / therapeutic use
  • Child
  • Graft vs Host Disease*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Transplantation Conditioning
  • Vidarabine

Substances

  • treosulfan
  • Vidarabine
  • Busulfan